Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder

201877 citationsJournal Articlebronze Open Access

Authors

Tracy L. Simpson · Seattle Institute for Biomedical and Clinical Research

Andrew J. Saxon · Seattle Institute for Biomedical and Clinical Research

Cynthia A. Stappenbeck · Seattle Institute for Biomedical and Clinical Research

Carol A. Malte · Seattle Institute for Biomedical and Clinical Research

Robert Lyons · Seattle Institute for Biomedical and Clinical Research

Dana Tell · Seattle Institute for Biomedical and Clinical Research

Abstract

Prazosin holds promise as a harm-reduction pharmacologic treatment for alcohol use disorder and deserves further evaluation by independent research groups.

Topics & Keywords

Neurotransmitter Receptor Influence on Behavior Nicotinic Acetylcholine Receptors Study Forensic Toxicology and Drug Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Psychiatry

Volume 175, Issue 12, pp. 1216-1224

DOI: 10.1176/appi.ajp.2018.17080913

Field-Weighted Citation Impact: 3.78